| 来曲唑与氨鲁米特对照治疗绝经后晚期乳腺癌113例 |
| |
| 引用本文： | 刘冬耕,管忠震,沈镇宙,韩企夏,宋三泰,刘晓晴.来曲唑与氨鲁米特对照治疗绝经后晚期乳腺癌113例[J].中国肿瘤临床(英文版),2004(2). |
| |
| 作者姓名： | 刘冬耕 管忠震 沈镇宙 韩企夏 宋三泰 刘晓晴 |
| |
| 作者单位： | 广州中山医科大学附属肿瘤医院 510060 |
| |
| 摘 要： | 目的对比来曲唑和氨鲁米特治疗妇女绝经后晚期乳腺癌患者的有效性和耐受性。方法采用开放、随机、多中心对照研究。患者随机分组接受口服来曲唑2.5mg.d~(-1)或氨鲁米特1g.d(-1)的对照治疗。结果来曲唑组(n=59)有效率23.73%(CR 2例,PR 12例,ITT 有效率21.88%),SD 20.31%(13例)。氨鲁米特组(n=54)有效率11.11%(CR 1例,PR 5例,ITT 有效率10.17%),SD 20.34%(12例),2组疗效无统计学差异(P>0.05)。来曲唑组和氨鲁米特组不良反应发生率分别为18.64%和42.11%,与治疗相关的不良反应发生率分别为13.56%和33.33%。比较2组总的和与治疗相关的不良反应发生率均以来曲唑组明显较低,P 值均为0.002。结论来曲唑对绝经后、ER/PR 阳性或不明的晚期乳腺癌患者有效率为23.73%,与氨鲁米特比较无统计学差异。但来曲唑不良反应较氨鲁米特明显低,可以代替氨鲁米特用于晚期绝经后受体阳性或不明乳癌患者的治疗。
|
| 关 键 词： | 来曲唑 氨鲁米特 晚期乳腺癌 |
Comparison of Letrozole and Aminoglutethimide in Treatment of 113 Cases of Postmenopausal Women with Advanced Breast Cancer |
| |
| LIU Donggeng GUAN Zhongzhen Cancer Center,Sun Yat-sen University of Medical Sciences,Guangzhou ,China
SHEN Zhenzhou HAN Qixia Tumor Hospital of Fudan University,Shanghai ,China
SONG Santai LIU Xiaoqing.Comparison of Letrozole and Aminoglutethimide in Treatment of 113 Cases of Postmenopausal Women with Advanced Breast Cancer[J].Chinese Journal of Clinical Oncology,2004(2). |
| |
| Authors: | LIU Donggeng GUAN Zhongzhen Cancer Center Sun Yat-sen University of Medical Sciences Guangzhou China
SHEN Zhenzhou HAN Qixia Tumor Hospital of Fudan University Shanghai China
SONG Santai LIU Xiaoqing |
| |
| Institution: | LIU Donggeng GUAN Zhongzhen Cancer Center,Sun Yat-sen University of Medical Sciences,Guangzhou 510060,China
SHEN Zhenzhou HAN Qixia Tumor Hospital of Fudan University,Shanghai 200032,China
SONG Santai LIU Xiaoqing The 307th Hospital,China Academy of Military Medical Sciences,Beijing 100039,China |
| |
| Abstract: | Objective:To compare the efficacy and tolerability of letrozole with aminoglutethimide(AG)in postmenopausal women with advanced breast cancer.Methods:The multicenter,randomized controlled clinical trial was conducted in 113 patients.They randomly received letrozole 2.5 mg once daily(letrozole group)or AG 250 mg 4 times daily(AG group)with hydrocortisone.Results:The OR in letrozole group was 23.73%(2 cases of CR and 12 cases of PR,ITT OR was 21.88%),which was higher than in AG group (the OR 11.11%,1 case of CR and 5 cases of PR,ITT 10.17%),but there was no statistically significant dif- ference(P>0.05).Adverse events(AE)and the treatment related AE(RAE)in letrozole group(n=59)was 18.54% and 13.56% respectively,significantly lower than those(42.11% and 33.33% respectively)in AG group(n=57,P=0.002).Conclusion:The OR of letrozole in the treatment of postmenopausal advanced breast cancer positive or unknown for hormonal receptor is 23.73%,showing no significant difference to that of AG.The AE of letrozole are significantly less than AG. |
| |
| Keywords: | letrozole aminoglutethimide advanced breast cancer |
| 本文献已被 CNKI 等数据库收录！ |
|
